New Research: 2 stocks to buy as Nifty50 heads towards 40,000
Here is the latest financial fact sheet of NOVARTIS. For more details, see the NOVARTIS quarterly results and NOVARTIS share price. For a sector overview, read our pharmaceuticals sector report.
1 Day | % | -0.5 |
No. of shares | m | 24.69 |
1 Week | % | 1.9 |
1 Month | % | 3.1 |
1 Year | % | 82.5 |
52 week H/L | Rs | 1,224.0/559.7 |
No. of Mths Year Ending |
12 Mar-19* |
12 Mar-20* |
12 Mar-21* |
12 Mar-22* |
12 Mar-23* |
5-Yr Chart Click to enlarge
|
---|
NOVARTIS EQUITY SHARE DATA | |||||||
---|---|---|---|---|---|---|---|
High | Rs | 980 | 780 | 770 | 1,099 | 763 | |
Low | Rs | 600 | 420 | 501 | 547 | 554 | |
Sales per share (Unadj.) | Rs | 198.7 | 177.5 | 154.5 | 162.0 | 153.4 | |
Earnings per share (Unadj.) | Rs | 21.0 | 4.1 | 8.5 | -1.5 | 41.9 | |
Diluted earnings per share | Rs | 21.0 | 4.1 | 8.5 | -1.5 | 41.9 | |
Cash flow per share (Unadj.) | Rs | 22.3 | 9.4 | 13.4 | 2.4 | 44.3 | |
Dividends per share (Unadj.) | Rs | 10.00 | 10.00 | 10.00 | 10.00 | 47.50 | |
Adj. dividends per share | Rs | 10.00 | 10.00 | 10.00 | 10.00 | 47.50 | |
Avg Dividend yield | % | 1.3 | 1.7 | 1.6 | 1.2 | 7.2 | |
Book value per share (Unadj.) | Rs | 309.2 | 293.2 | 289.2 | 281.1 | 314.2 | |
Adj. book value per share | Rs | 309.2 | 293.2 | 289.2 | 281.0 | 314.2 | |
Shares outstanding (eoy) | m | 24.69 | 24.69 | 24.69 | 24.69 | 24.69 | |
Price / Sales ratio | x | 4.0 | 3.4 | 4.1 | 5.1 | 4.3 | |
Avg P/E ratio | x | 37.7 | 147.0 | 75.1 | -546.3 | 15.7 | |
P/CF ratio (eoy) | x | 35.5 | 63.8 | 47.5 | 342.7 | 14.9 | |
Price / Book Value ratio | x | 2.6 | 2.0 | 2.2 | 2.9 | 2.1 | |
Dividend payout | % | 47.7 | 244.9 | 118.1 | -663.7 | 113.5 | |
Avg Mkt Cap | Rs m | 19,508 | 14,815 | 15,691 | 20,321 | 16,262 | |
Total wages/salary | Rs m | 1,171 | 1,139 | 1,085 | 1,019 | 356 |
NOVARTIS INCOME DATA | |||||||
---|---|---|---|---|---|---|---|
Net Sales | Rs m | 4,907 | 4,383 | 3,814 | 3,999 | 3,787 | |
Other income | Rs m | 784 | 364 | 342 | 336 | 581 | |
Total revenues | Rs m | 5,691 | 4,747 | 4,155 | 4,334 | 4,369 | |
Gross profit | Rs m | 121 | 117 | 257 | -229 | 651 | |
Depreciation | Rs m | 32 | 131 | 122 | 97 | 61 | |
Interest | Rs m | 16 | 64 | 77 | 48 | 18 | |
Profit before tax | Rs m | 858 | 286 | 400 | -38 | 1,154 | |
Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Tax | Rs m | 340 | 186 | 191 | -1 | 120 | |
Profit after tax | Rs m | 518 | 101 | 209 | -37 | 1,034 | |
Gross profit margin | % | 2.5 | 2.7 | 6.7 | -5.7 | 17.2 | |
Effective tax rate | % | 39.6 | 64.8 | 47.8 | 2.6 | 10.4 | |
Net profit margin | % | 10.6 | 2.3 | 5.5 | -0.9 | 27.3 |
NOVARTIS BALANCE SHEET DATA | |||||||
---|---|---|---|---|---|---|---|
Current assets | Rs m | 9,887 | 9,973 | 9,224 | 8,259 | 7,861 | |
Current liabilities | Rs m | 3,672 | 4,169 | 3,573 | 3,345 | 2,683 | |
Net working cap to sales | % | 126.7 | 132.4 | 148.2 | 122.9 | 136.7 | |
Current ratio | x | 2.7 | 2.4 | 2.6 | 2.5 | 2.9 | |
Inventory Days | Days | 754 | 136 | 1,161 | 1,059 | 1,201 | |
Debtors Days | Days | 34 | 31 | 37 | 41 | 35 | |
Net fixed assets | Rs m | 10,292 | 2,398 | 12,768 | 11,834 | 12,656 | |
Share capital | Rs m | 123 | 123 | 123 | 123 | 123 | |
"Free" reserves | Rs m | 7,511 | 7,117 | 7,018 | 6,816 | 7,634 | |
Net worth | Rs m | 7,634 | 7,240 | 7,141 | 6,939 | 7,757 | |
Long term debt | Rs m | 0 | 0 | 0 | 0 | 0 | |
Total assets | Rs m | 20,179 | 12,370 | 21,991 | 20,102 | 20,517 | |
Interest coverage | x | 54.9 | 5.5 | 6.2 | 0.2 | 66.9 | |
Debt to equity ratio | x | 0 | 0 | 0 | 0 | 0 | |
Sales to assets ratio | x | 0.2 | 0.4 | 0.2 | 0.2 | 0.2 | |
Return on assets | % | 2.6 | 1.3 | 1.3 | 0.1 | 5.1 | |
Return on equity | % | 6.8 | 1.4 | 2.9 | -0.5 | 13.3 | |
Return on capital | % | 11.4 | 4.8 | 6.7 | 0.1 | 15.1 | |
Exports to sales | % | 1.2 | 6.1 | 9.3 | 8.8 | 2.1 | |
Imports to sales | % | 0 | 0 | 0 | 0 | 0 | |
Exports (fob) | Rs m | 58 | 269 | 354 | 353 | 80 | |
Imports (cif) | Rs m | 0 | 0 | 0 | 0 | 0 | |
Fx inflow | Rs m | 58 | 269 | 354 | 353 | 80 | |
Fx outflow | Rs m | 1,326 | 1,420 | 974 | 798 | 946 | |
Net fx | Rs m | -1,269 | -1,152 | -621 | -445 | -866 |
NOVARTIS CASH FLOW | |||||||
---|---|---|---|---|---|---|---|
From Operations | Rs m | -1,943 | -231 | -692 | 387 | 448 | |
From Investments | Rs m | 2,742 | 559 | 952 | 870 | -1,533 | |
From Financial Activity | Rs m | -298 | -414 | -368 | -356 | -305 | |
Net Cashflow | Rs m | 501 | -86 | -109 | 901 | -1,389 |
Share Holding
Shareholding as on Dec 2023
|
Company Information
|
CHM: C Snook | COMP SEC: Nikhil Malpani | YEAR OF INC: 1947 | BSE CODE: 500672 | FV (Rs): 5 | DIV YIELD (%): 4.6 |
Read: NOVARTIS 2022-23 Annual Report Analysis
More Trading Company Fact Sheets: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES SUN PHARMA CIPLA
Compare NOVARTIS With: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES SUN PHARMA CIPLA
After opening the day on positive note, Indian share markets gained the momentum as the session progressed and ended on firm footing.